82 related articles for article (PubMed ID: 24119435)
21. Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002.
Lampe FC; Gatell JM; Staszewski S; Johnson MA; Pradier C; Gill MJ; de Lazzari E; Dauer B; Youle M; Fontas E; Krentz HB; Phillips AN
Arch Intern Med; 2006 Mar; 166(5):521-8. PubMed ID: 16534038
[TBL] [Abstract][Full Text] [Related]
22. Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome.
Tozzi V; Zaccarelli M; Bonfigli S; Lorenzini P; Liuzzi G; Trotta MP; Forbici F; Gori C; Bertoli A; Bellagamba R; Narciso P; Perno CF; Antinori A;
Antivir Ther; 2006; 11(5):553-60. PubMed ID: 16964822
[TBL] [Abstract][Full Text] [Related]
23. Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study.
Sheng WH; Hung CC; Kao JH; Chang SY; Chen MY; Hsieh SM; Chen PJ; Chang SC
Clin Infect Dis; 2007 Apr; 44(7):988-95. PubMed ID: 17342655
[TBL] [Abstract][Full Text] [Related]
24. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
[TBL] [Abstract][Full Text] [Related]
25. Early HIV viral load determination after initiating first-line antiretroviral therapy for indentifying patients with high risk of developing virological failure: data from a cohort study in a resource-limited setting.
Alvarez-Uria G; Naik PK; Pakam R; Midde M
Trop Med Int Health; 2012 Sep; 17(9):1152-5. PubMed ID: 22487689
[TBL] [Abstract][Full Text] [Related]
26. Clinical and virological characteristics of hepatitis B or C virus co-infection with HIV in Indonesian patients.
Anggorowati N; Yano Y; Heriyanto DS; Rinonce HT; Utsumi T; Mulya DP; Subronto YW; Hayashi Y
J Med Virol; 2012 Jun; 84(6):857-65. PubMed ID: 22499006
[TBL] [Abstract][Full Text] [Related]
27. Comparison of demographic characteristics and upper gastrointestinal endoscopy findings in HIV-positive, antiretroviral-treated patients with and without Helicobacter pylori coinfection.
Nkuize M; De Wit S; Muls V; Ntounda R; Gomez-Galdon M; Buset M
Helicobacter; 2012 Apr; 17(2):153-9. PubMed ID: 22404447
[TBL] [Abstract][Full Text] [Related]
28. Short communication: use of serum bilirubin levels as surrogate marker of early virological response to atazanavir-based antiretroviral therapy.
Morello J; Alvarez E; Cuenca L; Vispo E; González-Lahoz J; Soriano V; Rodríguez-Nóvoa S
AIDS Res Hum Retroviruses; 2011 Oct; 27(10):1043-5. PubMed ID: 21348813
[TBL] [Abstract][Full Text] [Related]
29. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.
Cozzi-Lepri A; Phillips AN; Clotet B; Mocroft A; Ruiz L; Kirk O; Lazzarin A; Wiercinska-Drapalo A; Karlsson A; Lundgren JD;
AIDS; 2008 Oct; 22(16):2187-98. PubMed ID: 18832882
[TBL] [Abstract][Full Text] [Related]
30. Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen.
Burgos J; Crespo M; Falcó V; Curran A; Imaz A; Domingo P; Podzamczer D; Mateo MG; Van den Eynde E; Villar S; Ribera E
J Antimicrob Chemother; 2012 Jun; 67(6):1453-8. PubMed ID: 22378681
[TBL] [Abstract][Full Text] [Related]
31. The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens.
Maggiolo F; Ripamonti D; Torti C; Arici C; Antinori A; Quiros-Roldan E; Minoli L; Sighinolfi L; Nasta P; Suter F;
Antivir Ther; 2006; 11(7):923-9. PubMed ID: 17302255
[TBL] [Abstract][Full Text] [Related]
32. Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus.
Berenguer J; von Wichmann MA; Quereda C; Miralles P; Mallolas J; López-Aldeguer J; Alvarez-Pellicer J; De Miguel J; Crespo M; Guardiola JM; Tellez MJ; Galindo MJ; Arponen S; Barquilla E; Bellón JM; González-García J;
J Antimicrob Chemother; 2011 Dec; 66(12):2843-9. PubMed ID: 21965432
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of drug resistance and importance of viral load measurements in Honduran HIV-infected patients failing antiretroviral treatment.
Murillo W; de Rivera IL; Parham L; Jovel E; Palou E; Karlsson AC; Albert J
HIV Med; 2010 Feb; 11(2):95-103. PubMed ID: 19686436
[TBL] [Abstract][Full Text] [Related]
34. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
[TBL] [Abstract][Full Text] [Related]
35. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
[TBL] [Abstract][Full Text] [Related]
36. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
37. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of starting first-line antiretroviral therapy in hepatitis B virus/HIV-coinfected patients in Ghana.
Chadwick D; Ankcorn M; Sarfo F; Phillips R; Fox Z; Garcia A; Appiah L; Bedu-Addo G; Geretti AM
J Antimicrob Chemother; 2012 Dec; 67(12):2939-42. PubMed ID: 22915461
[TBL] [Abstract][Full Text] [Related]
39. Boosted protease inhibitor monotherapy as a maintenance strategy: an observational study.
Guiguet M; Ghosn J; Duvivier C; Meynard JL; Gras G; Partisani M; Teicher E; Mahamat A; Rodenbourg F; Launay O; Costagliola D;
AIDS; 2012 Nov; 26(18):2345-50. PubMed ID: 22695301
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness and pitfalls of initial highly active antiretroviral therapy in HIV-infected patients in routine clinical practice.
Moreno A; Perez-Elías MJ; Casado JL; Muñoz V; Antela A; Dronda F; Navas E; Fortún J; Quereda C; Moreno S
Antivir Ther; 2000 Dec; 5(4):243-8. PubMed ID: 11142618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
